gSpiriva Delivers First Mover Advantage In US, Lupin Plans Europe Launch
Lucentis Biosimilar Filing Seen In FY25
Lupin’s Q2 margins jumped post launch of the first Spiriva generic in the US, encouraging launch plans for Europe and Canada. With four out of five plants clearing a regulatory overhang from earlier warning letters, the specialty engine is revving up though competition in first-to-file products launched earlier could dampen margins somewhat
